Unusual market activity is often the first sign that big changes are coming to a stock. Professional traders and large ...

AbbVie leads a Zacks Analyst Blog roundup highlighting strong pharma execution, AI-driven chip gains and an aviation rebound.

Based on the topline results from the EPCORE® DLBCL-1 trial, AbbVie along with partner Genmab will engage global regulatory authorities to discuss next steps NORTH ...

AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

AbbVie Inc. (NYSE:ABBV) is one of the best performing pharma stocks in 2025. AbbVie Inc. (NYSE:ABBV) was downgraded to Peer ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on AbbVie (ABBV – Research Report) and Glaukos (GKOS – Research Report) with bull ...

AbbVie slides after the company cut guidance, Wolfe Research downgraded the stock and the company pushed back on acquisition reports ...

AbbVie agrees to lower drug prices, invest $100 billion in the U.S., expand manufacturing, and secure tariff relief.

AbbVie has delivered strong YTD outperformance, with shares up nearly 30% and robust analyst optimism, but I maintain a 'Hold ...

AbbVie's Q1 2026 dividend increases 5.5% YOY, lagging both its past growth rates and the healthcare sector median. Learn more ...

Abbvie Inc. signed a $1.1 billion New Year’s Eve deal with China’s Zelgen Biopharmaceuticals Co. Ltd., gaining ex-China ...

Shares of AbbVie Inc. ABBV slipped 3.98% to $220.18 Monday, on what proved to be an all-around great trading session for the ...